CDR132L

CDR132L did not significantly improve percentage change in LVESVI compared with placebo at 6 months. CDR132L treatment consisted of three intravenous infusions given 28 days apart at weeks 0, 4, and 8. CDR132L was tested at 5 mg kg−1 and 10 mg kg−1 doses against placebo. The findings support further clinical investigation of CDR132L but do not establish clinical efficacy. CDR132L is a synthetic locked nucleic acid antisense oligonucleotide that inhibits microRNA-132. CDR132L produced dose-dependent reductions in plasma miR-132, with the largest reductions at 10 mg kg−1. CDR132L was well tolerated at both tested doses, with an adverse event profile similar to placebo. No renal, hepatic, hematologic, or cardiac toxicity was attributed to CDR132L.